25 - 27 October, 2016
Novotel Berlin Am Tiergarten, Berlin, Germany

Dr. Jonathan S. Mason

Senior Research Fellow, Head of CADD
Heptares Therapeutics, UK

Senior Research Fellow at Heptares Therapeutics in the UK leading Computer-Assisted Drug Design (CADD) approaches for GPCR structure-based drug design, leading the computational chemistry team.  35 years of global pharmaceutical drug discovery experience including senior roles in Lundbeck, Pfizer, BMS and RPR/Sanofi. Experienced leader and scientific expert for drug design technologies (computational medicinal chemistry / CADD, structural biology, in silico  ADME/tox etc).

16:30 GPCRs: What do the diversity of new X-ray structures tell us about rational compound and library design?

  • Implications for design from the new binding sites discovered in recent GPCR X-ray structures

  • Using water in binding to generate new and modified property compounds

  • New structure-based approaches for the rational design of potency, selectivity and kinetics

17:30 Building compound archives for future targets

  • Will the targets of the future be covered by the chemical matter of today?

  • Do we have the tools that can answer this question?

  • The interplay between druggability and ligandability

  • Future directions

Panel discussion will be followed by an Open Mic session: Join the discussion with the panel of experts and find collectively possible approaches and solutions

Check out the incredible speaker line-up to see who will be joining Dr. Jonathan S..

Download The Latest Agenda